Rentschler Biopharma, a global contract development and manufacturing organization (CDMO) for biopharmaceuticals, has hired several senior level, highly experienced biopharmaceutical executives. These important additions aim to enhance Rentschler Biopharma’s ability to effectively address the increasing demand to develop and manufacture complex biopharmaceuticals worldwide.
 
Dr. Günter Stempfer was named Head of Global Strategic Development. He previously supported Rentschler Biopharma in an operations consulting capacity. In this newly created role, he will work closely with the team to evaluate, define, and drive strategic initiatives and projects across all of the Company’s sites. Dr. Stempfer brings more than 25 years of experience in the biopharmaceutical industry, having held various leadership positions, most lately at Sandoz, Polpharma Biologics and Novartis Pharma.
 
Christiane Bardroff was named Senior Vice President Client Program Management. From her previous positions at Teva Biotech and Roche Penzberg, she brings extensive experience in the organization of complex projects. She will drive and add to the Company’s existing Client Program Management (CPM) function, enabling new dimensions of support and consulting for client partners.
 
Elke Ottenschläger was named Senior Vice President Clinical and Commercial Manufacturing. She joins the Company from Lonza, where she was Head Global Technical Functions and Head Global Tech Transfer. She will lead the production teams and will focus on implementing Rentschler Biopharma’s growth strategy at the Laupheim site, including increasing production capacity and further digitalizing and automating operations.
 
Dr. Christian Hunzinger, who initiated the CPM unit and shaped its growth over the past three years, has transitioned to the newly created position of Vice President Analytical Science, effective February 1, 2022. This role will enable the Company to effectively respond to the increasing client need for advanced in-process analytics for rapid, data-based development.
 
“To ensure that Rentschler Biopharma continues to effectively foresee and address our clients’ growing and changing needs, it is critical that we attract and retain highly qualified team members,” commented Dr. Frank Mathias, CEO of Rentschler Biopharma. “I am delighted to welcome Günter, Christiane, and Elke to Rentschler Biopharma. Each brings great expertise and knowledge that will further strengthen our client experience. I am also pleased that Christian will take on his important new role at the interface between Process Science and Quality Control. The additions and changes announced today are important as we help our clients to bring life-saving medicines to patients with serious or rare diseases.”